Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year Low – Here’s What Happened

Royalty Pharma plc (NASDAQ:RPRX) reached a new 52-week low during trading on Tuesday . The company traded as low as $24.70 and last traded at $25.00, with a volume of 4385083 shares traded. The stock had previously closed at $24.84.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RPRX. Citigroup decreased their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Price Performance

The stock has a 50-day moving average of $26.55 and a two-hundred day moving average of $27.19. The firm has a market cap of $14.42 billion, a price-to-earnings ratio of 12.68, a price-to-earnings-growth ratio of 4.36 and a beta of 0.46. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Institutional Trading of Royalty Pharma

A number of hedge funds have recently modified their holdings of RPRX. Blue Trust Inc. raised its position in Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 943 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma in the third quarter worth $61,000. EverSource Wealth Advisors LLC boosted its stake in shares of Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 655 shares in the last quarter. Transamerica Financial Advisors Inc. grew its holdings in Royalty Pharma by 99.9% during the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,729 shares during the last quarter. Finally, iA Global Asset Management Inc. raised its holdings in Royalty Pharma by 274.7% in the 2nd quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 4,683 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.